{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T01:31:19Z","timestamp":1765503079759,"version":"3.48.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Department of Medicine, University of Ottawa"},{"name":"Tier II Faculty of Medicine Research Chair in Inflammatory Bowel Diseases"},{"DOI":"10.13039\/100008572","name":"University of Ottawa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008572","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Northbridge Financial Corporation Chair in Inflammatory Bowel Disease"},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006126","name":"The Hospital for Sick Children","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006126","id-type":"DOI","asserted-by":"crossref"}]},{"name":"SickKids Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Individuals with inflammatory bowel diseases (IBD) are at increased risk of repeated disease-related hospital admissions, some of which may be preventable with targeted outpatient interventions. We assessed population-level trends in the rates of IBD-specific hospital readmission within 30 and 90\u2009days of index hospitalization among those with Crohn\u2019s disease (CD) and ulcerative colitis (UC) during a period marked by major changes to IBD management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We accessed Ontario health administrative datasets to study CD (2002-2017) and UC (2004-2020) patients hospitalized for IBD-specific indications. We compared IBD-specific 30-day and 90-day hospital readmission rates across 4 (UC) and 5 (CD) year time periods using multivariable logistic regression, controlling for age, sex, comorbidities, residential setting, household income, hospital type, and clustering of admissions within patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among CD patients, 30-day readmission rates decreased from 9.7% to 7.4%, and 90-day rates decreased from 16.0% to 14.1% between 2002-2007 and 2012-2017 periods. There was a higher likelihood of 30-day readmission during 2002-2007 (adjusted odds ratio [aOR] 1.32; 95% CI, 1.16-1.50) and 2007-2012 (aOR 1.15; 95% CI, 1.01-1.32), and of 90-day readmission during 2002-2007 (aOR 1.14; 95% CI, 1.03-1.26), as compared to 2012-2017. Among UC patients, readmission rates remained stable across time periods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Inflammatory bowel disease-related early rehospitalization risk has declined over time among individuals with CD but not among individuals with UC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jcag\/gwaf027","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:22:43Z","timestamp":1759234963000},"page":"260-266","source":"Crossref","is-referenced-by-count":0,"title":["Temporal trends in 30-day and 90-day hospital readmission rates among individuals with inflammatory bowel diseases in Ontario, Canada: a population-based study"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9727-701X","authenticated-orcid":false,"given":"Jonah S","family":"Moore","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Toronto , Toronto, Ontario,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7309-1316","authenticated-orcid":false,"given":"Claudia","family":"Dziegielewski","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology & Hepatology, University of California San Diego , San Diego, CA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Pugliese","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, University of Ottawa , Ottawa, Ontario, K1H 8L6,","place":["Canada"]},{"name":"ICES uOttawa , Ottawa, Ontario, K1Y 4E9,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8855-3598","authenticated-orcid":false,"given":"Eric I","family":"Benchimol","sequence":"additional","affiliation":[{"name":"SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children , Toronto, Ontario, M5G 1X8,","place":["Canada"]},{"name":"Child Health Evaluative Sciences, SickKids Research Institute , Toronto, Ontario, M5G 1X8,","place":["Canada"]},{"name":"ICES , Toronto, Ontario, M4N 3M5,","place":["Canada"]},{"name":"Department of Paediatrics and Institute of Health Policy, Management and Evaluation, University of Toronto , Toronto, Ontario, M5T 1P8,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay K","family":"Murthy","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, University of Ottawa , Ottawa, Ontario, K1H 8L6,","place":["Canada"]},{"name":"ICES uOttawa , Ottawa, Ontario, K1Y 4E9,","place":["Canada"]},{"name":"The Ottawa Hospital IBD Centre , Ottawa, Ontario, K1H 8L6,","place":["Canada"]},{"name":"Department of Medicine, University of Ottawa , Ottawa, Ontario, K1H 8L6,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"2025121120262677500_gwaf027-B1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017","volume":"5","author":"Collaborators GIBD","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025121120262677500_gwaf027-B2","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.14309\/ajg.0000000000002687","article-title":"Forecasting the incidence and prevalence of inflammatory bowel disease: a Canadian nationwide analysis","volume":"119","author":"Coward","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2025121120262677500_gwaf027-B3","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/jcag\/gwad008","article-title":"The 2023 impact of inflammatory bowel disease in Canada: direct health system and medication costs","volume":"6","author":"Kuenzig","year":"2023","journal-title":"J Can Assoc Gastroenterol"},{"key":"2025121120262677500_gwaf027-B4","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cgh.2018.02.015","article-title":"Annual burden and costs of hospitalization for high-need, high-cost patients with chronic gastrointestinal and liver diseases","volume":"16","author":"Nguyen","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025121120262677500_gwaf027-B5","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.cgh.2019.08.042","article-title":"Rate of risk factors for and interventions to reduce hospital readmission in patients with inflammatory bowel diseases","volume":"18","author":"Nguyen","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025121120262677500_gwaf027-B6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.14309\/ajg.0000000000000503","article-title":"Longitudinal trends in the direct costs and health care utilization ascribable to inflammatory bowel disease in the biologic era: results from a Canadian population-based analysis","volume":"115","author":"Targownik","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2025121120262677500_gwaf027-B7","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/apt.15511","article-title":"Declining hospitalisation and surgical intervention rates in patients with Crohn\u2019s disease: a population-based cohort","volume":"50","author":"Rahman","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121120262677500_gwaf027-B8","first-page":"48","article-title":"The burden of IBD hospitalization in Canada: an assessment of the current and future burden in a nation-wide analysis","author":"Coward","year":"2023"},{"key":"2025121120262677500_gwaf027-B9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/gutjnl-2017-315568","article-title":"Natural disease course of Crohn\u2019s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study","volume":"68","author":"Burisch","year":"2019","journal-title":"Gut"},{"key":"2025121120262677500_gwaf027-B10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/ecco-jcc\/jjy154","article-title":"Natural disease course of ulcerative colitis during the first five years of follow-up in a European population-based inception cohort-an Epi-IBD study","volume":"13","author":"Burisch","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2025121120262677500_gwaf027-B11","first-page":"474","article-title":"Inflammatory bowel disease readmissions are associated with utilization and comorbidity","volume":"25","author":"Cohen-Mekelburg","year":"2019","journal-title":"Am J Manag Care"},{"key":"2025121120262677500_gwaf027-B12","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/gutjnl-2019-318440","article-title":"Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study","volume":"69","author":"Murthy","year":"2020","journal-title":"Gut"},{"key":"2025121120262677500_gwaf027-B13","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1093\/jcag\/gwad015","article-title":"The 2023 impact of inflammatory bowel disease in Canada: treatment landscape","volume":"6","author":"Murthy","year":"2023","journal-title":"J Can Assoc Gastroenterol"},{"key":"2025121120262677500_gwaf027-B14","article-title":"Treat to target: a proposed new paradigm for the management of Crohn\u2019s disease","author":"Bouguen","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025121120262677500_gwaf027-B15","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2025121120262677500_gwaf027-B16","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","article-title":"Early combined immunosuppression for the management of Crohn\u2019s disease (REACT): a cluster randomised controlled trial","volume":"386","author":"Khanna","year":"2015","journal-title":"Lancet"},{"key":"2025121120262677500_gwaf027-B17","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet"},{"key":"2025121120262677500_gwaf027-B18","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/ibd\/izad020","article-title":"Hospitalization rates for inflammatory bowel disease are decreasing over time: a population-based cohort study","volume":"29","author":"Buie","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2025121120262677500_gwaf027-B19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12876-021-01781-x","article-title":"Hospitalization and surgery rates in patients with inflammatory bowel disease in Brazil: a time-trend analysis","volume":"21","author":"Palacio","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"2025121120262677500_gwaf027-B20","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1001\/archinte.160.8.1074","article-title":"Hospital readmissions as a measure of quality of health care: advantages and limitations","volume":"160","author":"Benbassat","year":"2000","journal-title":"Arch Intern Med"},{"key":"2025121120262677500_gwaf027-B21","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/gut.2009.188383","article-title":"Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data","volume":"58","author":"Benchimol","year":"2009","journal-title":"Gut"},{"key":"2025121120262677500_gwaf027-B22","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jclinepi.2014.02.019","article-title":"Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada","volume":"67","author":"Benchimol","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"2025121120262677500_gwaf027-B23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2025121120262677500_gwaf027-B24","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.cgh.2018.11.003","article-title":"Upfront combination therapy, compared with monotherapy, for patients not previously treated with a biologic agent associates with reduced risk of inflammatory bowel disease-related complications in a population-based cohort study","volume":"17","author":"Targownik","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025121120262677500_gwaf027-B25","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/j.cgh.2022.02.021","article-title":"Earlier anti-TNF initiation leads to long-term lower health care utilization in Crohn\u2019s disease but not in ulcerative colitis","volume":"20","author":"Targownik","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025121120262677500_gwaf027-B26","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3109\/00365521.2015.1020862","article-title":"Early readmission in patients hospitalized for ulcerative colitis: incidence and risk factors","volume":"50","author":"Tinsley","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"2025121120262677500_gwaf027-B27","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1097\/MIB.0000000000000537","article-title":"Risk factors for rehospitalization within 90 days in patients with inflammatory bowel disease","volume":"21","author":"Allegretti","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2025121120262677500_gwaf027-B28","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/MIB.0000000000001121","article-title":"Modifiable risk factors for hospital readmission among patients with inflammatory bowel disease in a nationwide database","volume":"23","author":"Barnes","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2025121120262677500_gwaf027-B29","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1007\/s10620-020-06746-w","article-title":"Increasing prevalence of frailty and its association with readmission and mortality among hospitalized patients with IBD","volume":"66","author":"Faye","year":"2021","journal-title":"Dig Dis Sci"},{"key":"2025121120262677500_gwaf027-B30","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.cgh.2020.08.010","article-title":"Frailty is independently associated with mortality and readmission in hospitalized patients with inflammatory bowel diseases","volume":"19","author":"Qian","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025121120262677500_gwaf027-B31","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1093\/jcag\/gwad013","article-title":"The 2023 impact of inflammatory bowel disease in Canada: special populations-IBD in seniors","volume":"6","author":"Shaffer","year":"2023","journal-title":"J Can Assoc Gastroenterol"},{"key":"2025121120262677500_gwaf027-B32","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5152\/tjg.2022.21711","article-title":"Low muscle mass is associated with readmission for inflammatory bowel disease","volume":"34","author":"Liu","year":"2023","journal-title":"Turk J Gastroenterol"},{"key":"2025121120262677500_gwaf027-B33","doi-asserted-by":"crossref","first-page":"467","DOI":"10.23736\/S0026-4806.21.07442-5","article-title":"Nonattendance to gastroenterologist follow-up after discharge is associated with a thirty-days re-admission in patients with inflammatory bowel disease: a multicenter study","volume":"112","author":"Sbeit","year":"2021","journal-title":"Minerva Med"},{"key":"2025121120262677500_gwaf027-B34","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/jcag\/gwae054","article-title":"A multivariable prediction model to stratify risk of 90-day rehospitalization among adults with ulcerative colitis","volume":"8","author":"Dziegielewski","year":"2025","journal-title":"J Can Assoc Gastroenterol"},{"key":"2025121120262677500_gwaf027-B35","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12876-024-03226-7","article-title":"Clinical and health care utilization variables can predict 90-day hospital re-admission in adults with Crohn\u2019s disease for point of care risk evaluation","volume":"24","author":"Dziegielewski","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"2025121120262677500_gwaf027-B36","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/apt.12073","article-title":"Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis","volume":"36","author":"Murthy","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121120262677500_gwaf027-B37","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.cgh.2006.12.028","article-title":"Impact of Clostridium difficile on inflammatory bowel disease","volume":"5","author":"Issa","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025121120262677500_gwaf027-B38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/gut.2007.128231","article-title":"Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease","volume":"57","author":"Ananthakrishnan","year":"2008","journal-title":"Gut"},{"key":"2025121120262677500_gwaf027-B39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/apt.17777","article-title":"Recent trends and risk factors associated with Clostridioides difficile infections in hospitalized patients with inflammatory bowel disease","volume":"59","author":"Spartz","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121120262677500_gwaf027-B40","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/ibd.21457","article-title":"Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease","volume":"17","author":"Ananthakrishnan","year":"2011","journal-title":"Inflamm Bowel Dis"}],"container-title":["Journal of the Canadian Association of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcag\/advance-article-pdf\/doi\/10.1093\/jcag\/gwaf027\/64959749\/gwaf027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcag\/advance-article-pdf\/doi\/10.1093\/jcag\/gwaf027\/64959749\/gwaf027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T01:26:37Z","timestamp":1765502797000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcag\/article\/8\/6\/260\/8304366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jcag\/gwaf027","relation":{},"ISSN":["2515-2084","2515-2092"],"issn-type":[{"type":"print","value":"2515-2084"},{"type":"electronic","value":"2515-2092"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,27]]}}}